Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Target Validation, 2011
    Ghrelin Agonist as a Novel Therapeutic Approach to Alleviate Gut Dysmotility and Levodopa-inhibited Gastric Emptying in PD Models

    Objective/Rationale:

    Patients with Parkinson’s disease (PD) have altered progression of ingested aliments/liquid from their stomach to the intestine, as well as suffer from constipation, and there is...

  • MJFF Research Grant, 2011
    Structural, Post-translational Modification and Small Chemical Approaches to Understand LRRK2 Function in PD

    Promising Outcomes of Original Grant:
    Our original goal was to (1) establish electron microscopy (EM)-based dimeric structural assays for the LRRK2 protein and (2) develop high-throughput kinase assays...

  • LRRK2, 2011
    Analytic Models in Biomarker Development

    Objective/Rationale:
    Non-invasive tests or biomarkers may aid clinical trials if they help to identify a subgroup of individuals at high risk of Parkinson's disease (PD), or if they are able to...

  • Therapeutics Development Initiative, 2011
    Testing of Ambroxol in the Thy1-Alpha-Synuclein Pre-clinical Model of Parkinson's disease

    Objective/Rationale:
    Biochemical evidence suggests that blocking the maturation of a natural enzyme, glucocerebrosidase (GCase), can cause the build-up of alpha-synuclein deposits in neurons.  Such...

  • Research Grant, 2011
    Pre-clinical Development of Encapsulated Cell Biodelivery of GDNF for Parkinson's Disease

    Objective/Rationale:
    Glial cell line-derived neurotrophic factor (GDNF) is a protein that can aid in survival of the dopamine cells that die in Parkinson’s disease (PD). Treatment with GDNF in PD has...

  • LRRK2 Cohort Consortium, 2011
    Autonomic Profiles of LRRK2 Mutation Carriers with Parkinson’s Disease and Non-manifesting, First-degree Relatives

    Objective/Rationale:
    Autonomic disturbances are common symptoms of Parkinson’s disease (PD). We propose to analyze data on autonomic function collected from PD patients and relatives of PD patients...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.